Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

CMO Letter to Reduce Unnecessary Antibiotic Prescribing and Broad Spectrum Prescribing Winter 2018-9 (CMO2018-9)

2. mars 2020 oppdatert av: Public Health England

A Randomized Controlled Trial of Behaviourally Informed Feedback Letters Sent by the Chief Medical Officer on the Amount of Antibiotics and the Percentage of Broad Spectrum Antibiotics Prescribed in Primary Care

This trial aims to reduce unnecessary prescription of antibiotics and broad spectrum antibiotics by general practitioners (GPs) in England. Unnecessary prescriptions are defined as those that do not improve patient health outcomes. The intervention is to send GPs a letter from the Chief Medical Officer (CMO) that gives feedback on their practice's prescribing levels. Specifically the sample was GPs whose practices whose prescribed more than 1.161 items per STAR-PU or whose practices prescribed more that .965 items per STAR-PU and greater than 10% broad spectrum items. The intervention groups received a letter telling them they are among the highest prescribers of either their total or broad spectrum antibiotics, with a graph showing their prescribing compared to average prescribing ("their peers"). The letter also contained a leaflet to help GPs discuss self-care advice with patients and some advice to use delayed prescriptions. The investigators hypothesize that the antibiotic prescribing rate in will be lower for the treatment group compared to the control group, following the receipt of the letter.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

7000

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • GP practices that prescribed more than 1.161 Antibacterial Items/STAR-PU for the twelve months (June 2017 - May 2018)
  • GP practices that prescribed more than 0.965 Antibacterial Items/STAR-PU and also more than 10% broad spectrum items for the twelve months (June 2017 - May 2018).

Exclusion Criteria:

  • none

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: high total and high broad spectrum prescribing letter
social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
letter with the percentile prescribing the practice is on and a bar chart, comparing prescribing to the national average
Aktiv komparator: high total and high broad spectrum prescribing control
standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive the standard practice overall prescribing letter as a control
social norm feedback letter used as standard practice, without specific information about the prescribing percentile
Eksperimentell: high total prescribing only intervention letter
social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive a letter that has specific information about the percentile they are on for overall prescribing and a bar chart representing their overall prescribing compared to the average
letter with the percentile prescribing the practice is on and a bar chart, comparing prescribing to the national average
Aktiv komparator: high total prescribing control letter
standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive the standard practice overall prescribing letter as a control
social norm feedback letter used as standard practice, without specific information about the prescribing percentile
Eksperimentell: moderate total prescribing and high broad spectrum letter
social norm feedback letter with bar chart GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum will receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
letter with the percentile prescribing the practice is on and a bar chart, comparing prescribing to the national average
Ingen inngripen: moderate total prescribing and high broad spectrum control
GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive no letter, which is standard practice, as a control.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
total antibiotic prescribing weighted by Specific Therapeutic group Age-sex Related Prescribing Unit (STAR-PU) in November for each GP practice
Tidsramme: 1 month
antibiotic prescribing weighted by Specific Therapeutic group Age-sex Related Prescribing Unit (STAR-PU)
1 month
total broad spectrum antibiotic prescribing weighted by STAR-PU in November for each GP practice
Tidsramme: 1 month
broad spectrum antibiotic prescribing weighted by Specific Therapeutic group Age-sex Related Prescribing Unit (STAR-PU)
1 month
percentage broad spectrum antibiotic prescribing in November for each GP practice
Tidsramme: 1 month
percentage broad spectrum antibiotic prescribing
1 month
total non-broad spectrum antibiotic prescribing weighted by STAR-PU in November for each GP practice
Tidsramme: 1 month
total overall antibiotic prescribing minus total broad spectrum antibiotic prescribing
1 month
total antibiotic prescribing weighted by STAR-PU in December for each GP practice
Tidsramme: 2 months
antibiotic prescribing weighted by Specific Therapeutic group Age-sex Related Prescribing Unit (STAR-PU)
2 months
total broad spectrum antibiotic prescribing weighted by STAR-PU in December for each GP practice
Tidsramme: 2 months
2 months
percentage broad spectrum antibiotic prescribing in December for each GP practice
Tidsramme: 2 months
2 months
total non-broad spectrum antibiotic prescribing weighted by STAR-PU in December for each GP practice
Tidsramme: 2 months
2 months
total antibiotic prescribing in January weighted by STAR-PU for each GP practice
Tidsramme: 3 months
3 months
total broad spectrum antibiotic prescribing weighted by STAR-PU in January for each GP practice
Tidsramme: 3 months
3 months
percentage broad spectrum antibiotic prescribing in January for each GP practice
Tidsramme: 3 months
3 months
total non-broad spectrum antibiotic prescribing weighted by STAR-PU in January for each GP practice
Tidsramme: 3 months
3 months
total antibiotic prescribing weighted by STAR-PU in February for each GP practice
Tidsramme: 4 months
4 months
total broad spectrum antibiotic prescribing weighted by STAR-PU in February for each GP practice
Tidsramme: 4 months
4 months
percentage broad spectrum antibiotic prescribing in February for each GP practice
Tidsramme: 4 months
4 months
total non-broad spectrum antibiotic prescribing weighted by STAR-PU in February for each GP practice
Tidsramme: 4 months
4 months
total antibiotic prescribing weighted by STAR-PU in March for each GP practice
Tidsramme: 5 months
5 months
total broad spectrum antibiotic prescribing weighted by STAR-PU in March for each GP practice
Tidsramme: 5 months
5 months
percentage broad spectrum antibiotic prescribing in March for each GP practice
Tidsramme: 5 months
5 months
total non-broad spectrum antibiotic prescribing weighted by STAR-PU in March for each GP practice
Tidsramme: 5 months
5 months
total antibiotic prescribing weighted by STAR-PU in April for each GP practice
Tidsramme: 6 months
6 months
total broad spectrum antibiotic prescribing weighted by STAR-PU in April for each GP practice
Tidsramme: 6 months
6 months
percentage broad spectrum antibiotic prescribing in April for each GP practice
Tidsramme: 6 months
6 months
total non-broad spectrum antibiotic prescribing weighted by STAR-PU in April for each GP practice
Tidsramme: 6 months
6 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. november 2018

Primær fullføring (Faktiske)

30. april 2019

Studiet fullført (Faktiske)

30. mai 2019

Datoer for studieregistrering

Først innsendt

27. februar 2019

Først innsendt som oppfylte QC-kriteriene

1. mars 2019

Først lagt ut (Faktiske)

5. mars 2019

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. mars 2020

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. mars 2020

Sist bekreftet

1. desember 2018

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • R&D 193

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere